This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Taisho Pharmaceutical Co., Ltd.
Drug Names(s): TS-021
Description: TS-021 is an inhibitor of di-peptidyl peptidase-IV (DPP-IV), an enzyme that breaks down glucagon-like peptide-1 (GLP-1). GLP-1 binds to receptors on pancreatic beta cells stimulating the release of the hormone insulin. GLP-1 also reduces the secretion of glugacon, a hormone produced by the pancreas that stimulates the liver to convert glycogen to glucose thus increasing blood sugar levels. By delaying the degradation of GLP-1, DPP-IV inhibitors extends the action of insulin while also suppressing the release of glucagon.
Deal Structure: On July 6, 2005, Lilly licensed TS-021 from Taisho Pharmaceutical. Under the terms of the agreement, Taisho granted Lilly exclusive rights for the development and commercialization of TS-021 worldwide, except Japan and China, where Taisho retained the rights. Taisho will supply Lilly the bulk drug for their development and commercialization. Taisho, under certain circumstances, may be able to co-promote with Lilly in the US and other designated countries.
In August 2006, Taisho Pharmaceutical and Eli Lilly terminated a license agreement for TS-021. The decision was made by the fact that pre-clinical study results did not meet certain criteria set by Lilly.
Taisho granted Lilly exclusive rights for development and commercialization of TS-021 worldwide except for Japan and China under the license agreement executed in July 2005. Taisho will nevertheless continue development of TS-021 in Japan by itself, and Taisho's affiliate company, Taisho Pharmaceutical R&D Inc. will pursue the...See full deal structure in Biomedtracker
Pink Sheet Ten Programs To Watch Out For At ASCO
Additional information available to subscribers only: